I have tried sema, tirz and reta, tritrating up on each one to be cautious of side effects. I have had no gastro intestinal problems whatsoever. However, in each case, when I reached a moderate dose I began to have sensation of allodynia or dysesthesia. This occured far below what most studies...
Drs Benjamin Levy III and Michael Camilleri discuss managing GLP-1 gastrointestinal adverse effects, preparing patients for endoscopy, and treating obesity.
32:00-44:15
Case: 54-Year-Old Man with Vaculogenic ED
Case Study: Body Composition Transformation
THE EFFECTS OF COMBINED THERAPY ON HORMONAL AND METABOLIC PERFORMANCE
DATA-DRIVEN INSIGHTS: QUANTITATIVE BIOMARKER CHANGES...
Rising patient interest in TRT, GLP-1s, and peptide stacking requires clinicians to anchor conversations in evidence tiers, use baseline DEXA scans to monitor body composition, and engage patient goals without endorsing unsupported claims, according to Jean Cunningham, PharmD, BCPS...
* They unpack the myths, the mechanisms, and the real impact behind these breakthrough therapies, and don’t shy away from the harder questions around access, affordability
From Hollywood headlines to hospital hallways, the world’s sudden fascination with GLP-1s makes it hard to separate...
GLP-1 receptor agonists are one of the most revolutionary new classes of drugs in decades. In this episode of Healthy Dialogue, host Derek C. Angus, MD, MPH, sat down with Jens Juul Holst, MD, DMSc, and Lotte Bjerre Knudsen, DMSc, 2 pioneering scientists behind the discovery and development of...
In this episode, Dr. Rena Malik, MD explores the evolving landscape of anabolic peptides and their impact on men’s health, hormone optimization, and overall well-being. Joined by Dr. Mohit Khera, Dr. Kevin Campbell, and Dr. Alex Tatem, the discussion unpacks what peptides are, the challenges of...
Semaglutide, sold as Ozempic and Wegovy, and tirzepatide, sold as Zepbound and Mounjaro, are new therapies for weight loss that actually work, helping millions around the world to feel better. But some people are fearful of side effects, such as loss of muscle mass. Are their fears warranted...
* Dr. le Roux shares exclusive insights into the Phase 3 data for #Survodutide (Boehringer Ingelheim’s dual GLP-1/glucagon agonist), including its groundbreaking impact on visceral fat and #FattyLiverDisease (MASLD/MASH) via the SYNCHRONIZE trials.
In this #DoctorPodcasts Episode 149, we...
Truly impressive!
* the really exciting data of SYNCHRONIZE-1 was not the weight loss it was actually the metabolic health gains so we see that there was an improvement in glycemia and blood pressure but there was a. 63% REDUCTION IN FAT IN THE LIVER so imagine you had 16% weight loss but 25%...
Carel le Roux is a Professor of Experimental Pathology at University College Dublin, Director of the Metabolic Medicine Group, and one of the world's leading researchers on how the gut communicates with the brain. He completed his PhD at Imperial College London, where he conducted foundational...
Nature staff discuss preliminary data on the effects of GLP-1 drugs on male fertility, plus a two-year trial of a brain-computer interface.
Timestamps
00:18 Brain-computer interface makes a life-changing impactNature: At-home brain implant gives man with motor neuron disease his daily life...
Dr. Andres Guillen Lozoya discusses findings from, "Testosterone Levels Improve in Men under GLP-1 Receptor Agonist Therapy.” This study aimed to evaluate changes in total and free testosterone before and after GLP-1RA therapy in men
In this episode of Science Quickly, Scientific American’s associate health editor Lauren Young joins host Kendra Pierre-Louis to talk about how the story of GLP‑1 drugs such as Ozempic, Wegovy and Mounjaro is evolving. We trace GLP-1s’ origins as type 2 diabetes treatments, their rise as...
Are GLP-1 agonists like Ozempic and Mounjaro the future of healthcare or a risk to your health? We break down the latest data on weight loss medication efficacy, common side effects, and the truth about muscle mass loss (sarcopenia).
In This Episode:
Dr. Jordan Feigenbaum and Dr. Austin...
In this video, David Kerr, MD examines the complex relationship between GLP-1 receptor agonists and gastrointestinal health. While these agents are highly effective for treating type 2 diabetes and obesity, a large-scale meta-analysis of over five million individuals suggests a nuanced...
Amy M. Pearlman, MD, Co-Founder, Prime Institute, Coral Gables, Florida, discusses the evolving role of testosterone. She centers the intersection of testosterone therapy and glucagon-like peptide-1 (GLP-1) medications, highlighting clinical considerations increasingly relevant to urology...
* we discuss what a recently rolled-out GLP-1 pill, the first of its kind approved for obesity, could mean for the future of weight loss.
Drugs known as glucagon-like peptide-1 receptor agonists, colloquially called GLP-1 medications, have gone from relatively obscure diabetes...
In this episode, Dr. Spencer Nadolsky discusses the transformative role of GLP-1 medications in obesity treatment. He explains the mechanism of GLP-1, its rise in popularity, associated risks, and the importance of personalized medicine. The conversation also touches on the significance of...
*This discussion explores why libido is frequently ignored and how it differs from arousal, performance, orgasm, and ejaculation. It highlights the brain as the primary sexual organ and explains how psychological factors such as stress, anxiety, depression, and chronic fatigue can significantly...
New drug candidates could transform the obesity treatment landscape again, as pill formulations and multi-agonist treatments undergo clinical trials. Endocrine Society experts Priya Jaisinghani, MD, DABOM, and Mehmet Furkan Burak, MD, discussed how emerging treatments could improve obesity...
Figure 1. Comparative overview of therapeutic approaches for male hypogonadism and metabolic dysfunction. The figure summarizes the key advantages and disadvantages of three main management modalities: GLP-1 receptor agonists (GLP-1 RAs), lifestyle modification (diet and exercise), and...
Retatrutide entered 2026 with impressive Phase 2 data. Five positive Phase 3 studies have since changed the discussion.
The strongest obesity trial reported 70.3 pounds of average weight loss with 12 mg over 80 weeks. A two-year extension involving people who started with a BMI of at least 35...
Newly joined member here but have been lurking for 6mo learning and absorbing as much as I can here. Appreciate what an incredible resource this site is and the members contributing. I fell into the trap of eating poorly, drinking often, and spiraling my weight out of control in the last few...
In this episode of On the Edge of Breakthrough, host Dr. Monty Pal sits down with Dr. Charles Brenner, an internationally recognized expert in metabolism and the founding Chair of the Department of Diabetes & Cancer Metabolism at City of Hope. Together, they explore the metabolic links between...
* Among the human studies, 9 evaluated testosterone levels (total and/or free), 6 reported on gonadotropins (LH, FSH), and 5 assessed clinical hypogonadal symptoms such as libido and erectile function. In total, 7 human studies demonstrated a statistically significant increase in testosterone...
In this episode of You Are Not Broken, Dr. Kelly Casperson sits down with endocrinologist and obesity medicine expert Dr. Rocio Salas-Whalen for a deep dive into GLP-1 medications (like Ozempic, Wegovy, and Mounjaro).
They cover everything you should be asking but probably haven’t heard...
https://dom-pubs.pericles-prod.literatumonline.com/doi/10.1111/dom.16612
Abstract
Aims
Nearly 42% of adults in the United States have obesity, a significant risk factor for many cardiometabolic diseases and cancers. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are promising...
This article outlines a comprehensive strategy for optimizing fat loss and muscle preservation, primarily discussed within the context of an online forum dedicated to men's health, ExcelMale.com. The core of the strategy involves a multi-faceted approach combining specific pharmacotherapies...